Takeda responds to the FDA advisory committee recommendation
... The breadth and depth of ACTOS data encompassing more than 16,000 patients over the past 10 yearsis consistent: Short- and long-term studies, both prospective and observational, s...Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
LINCOLNSHIRE, Ill. Takeda Global Research & Development Center (TGR&D) today announced that the company has submitted a New Drug Application (NDA) for an extended-release version of the combination medication ACTOplus met (pioglitazone HCl and metformin HCl) to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes. This new formulation (ACTOplus met XR) wou...Takeda submits new drug application for combination type 2 diabetes medication
LINCOLNSHIRE, Ill., June 30, 2005 Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Takeda submitted a separate NDA for a combination of pioglitazone...